Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma

Neuro-Oncology

Volumn 17, Issue 8, 2015, Pages 1139-1147

  Kickingereder, Philipp ^a   Wiestler, Benedikt ^a,b   Burth, Sina ^a   Wick, Antje ^a   Nowosielski, Martha ^c   Heiland, Sabine ^a   Schlemmer, Heinz Peter ^b   Wick, Wolfgang ^a,b   Bendszus, Martin ^a   Radbruch, Alexander ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Bevacizumab; Biomarker; Cerebral blood volume; Glioblastoma; R CBV

Indexed keywords

ALKYLATING AGENT; BEVACIZUMAB; GADOTERATE MEGLUMINE; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; TUMOR MARKER;

ARTICLE; BRAIN BLOOD VOLUME; CANCER RECURRENCE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DRUG EFFICACY; FOLLOW UP; GLIOBLASTOMA; HAZARD RATIO; HUMAN; LOG RANK TEST; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SUSCEPTIBILITY WEIGHTED IMAGING; TREATMENT RESPONSE; ADULT; AGED; BRAIN CORTEX; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; MORTALITY; PROCEDURES; TREATMENT OUTCOME; VASCULARIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; BEVACIZUMAB; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CEREBRAL CORTEX; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84942552483     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov028     Document Type: Article

References (29)

1. Wong ET, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw. 2008;6(5):515-522.
2. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610-622.
3. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11): 1963-1972.
4. Leu K, Pope WB, Cloughesy TF, et al. Imaging biomarkers for antiangiogenic therapy in malignant gliomas. CNS Oncol. 2013; 2(1):33-47.
5. Nowosielski M, Wiestler B, Goebel G, et al. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology. 2014;82(19):1684-1692.
6. Hu LS, Eschbacher JM, Dueck AC, et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol. 2012; 33(1):69-76.
7. Kong DS, Kim ST, Kim EH, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol. 2011; 32(2):382-387.
8. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247(2):490-498.
9. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol. 2000;21(5): 901-909.
10. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108(9):3749-3754.
11. Pechman KR, Donohoe DL, Bedekar DP, et al. Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume. J Neurooncol. 2011;105(2):233-239.
12. Vredenburgh JJ, Cloughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010;15(12): 1329-1334.
13. Kickingereder P, Wiestler B, Sahm F, et al. Primary Central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology. 2014;272(3):843-850.
14. Mouridsen K, Christensen S, Gyldensted L, et al. Automatic selection of arterial input function using cluster analysis. Magn Reson Med. 2006;55(3):524-531.
15. Wu O, Ostergaard L, Weisskoff RM, et al. Tracer arrival timing-insensitive technique for estimating flow in MR perfusion-weighted imaging using singular value decomposition with a block-circulant deconvolution matrix. Magn Reson Med. 2003; 50(1):164-174.
16. Ostergaard L, Weisskoff RM, Chesler DA, et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med. 1996;36(5):715-725.
17. Zhang W, Kreisl T, Solomon J, et al. Acute effects of bevacizumab on glioblastoma vascularity assessed with DCE-MRI and relation to patient survival. Paper presented at: The International Society for Magnetic Resonance in Medicine, Hawaii, USA, 2009.
18. Verhoeff JJ, Lavini C, van Linde ME, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol. 2010;21(8):1723-1727.
19. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009;69(13):5296-5300.
20. Schmainda KM, Prah M, Connelly J, et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol. 2014;16(6):880-888.
21. Ellingson BM, Sahebjam S, Kim HJ, et al. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. AJNR Am J Neuroradiol. 2014;35(4):673-679.
22. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182-189.
23. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014; 15(9):943-953.
24. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
25. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487-1495.
26. Kickingereder P, Dorn F, Blau T, et al. Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature. Radiat Oncol. 2013;8:52.
27. Song YS, Choi SH, Park CK, et al. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis. Korean J Radiol. 2013;14(4): 662-672.
28. Ellingson BM, Zaw T, Cloughesy TF, et al. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. J Magn Reson Imaging. 2012;35(6):1472-1477.
29. European Organisation for Research and Treatment of Cancer-EORTC. Bevacizumab and Lomustine for Recurrent GB. Available at: http://clinicaltrials.gov/show/NCT01290939. Accessed February 21, 2015.